Current pharmacological management in Juvenile Huntington's disease

Lisa Robertson, Helen Santini, Kirsty L. O'Donovan, Ferdinando Squitieri, Roger A. Barker, Maria Rakowicz, G. Bernhard Landwehrmeyer, Oliver Quarrell

Research output: Contribution to journalArticlepeer-review


Background: The clinical presentation of Juvenile Huntington's Disease (JHD) can be very different from adultonset HD with little evidence to guide symptomatic management. Aim: To survey the current use of pharmacological treatments for JHD. Methods: Patients were identified through the HD Association, Hospital Doctors and the European Huntington's Disease Network REGISTRY study. Results: The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and antiparkinsonian medications (15/45). 5 patients were taking more than 8 medications. Conclusions: The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

Original languageEnglish
Article numberecurrents.RRN1304
JournalPLoS Currents
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Medicine (miscellaneous)


Dive into the research topics of 'Current pharmacological management in Juvenile Huntington's disease'. Together they form a unique fingerprint.

Cite this